文献速递慢性肾脏病

超重与肥胖与常染色体显性多囊肾病进展

Overweight and Obesity and Progression of ADPKD.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-06-11

基于TEMPO 3:4试验中1312例早期常染色体显性多囊肾病(ADPKD)患者,按基线体重指数(BMI)分为正常体重、超重和肥胖组,分析BMI与肾脏总体积(TKV)及估算肾小球滤过率(eGFR)变化的关系。结果显示,超重和肥胖独立关联TKV增长更快,但与eGFR下降无关,且托伐普坦疗效不受BMI分组影响。

要点

  • 超重和肥胖与ADPKD患者肾脏总体积增长独立相关。
  • BMI与eGFR下降斜率无显著关联。
  • 托伐普坦疗效不受BMI分组影响。

核心结论

  • 超重和肥胖与ADPKD患者肾脏增长强烈独立相关,但与eGFR下降无关,且托伐普坦疗效不受BMI分类影响。

研究设计与样本

  • TEMPO 3:4试验事后分析,纳入1312例早期ADPKD患者(平均eGFR 78±22 ml/min/1.73 m2),按基线BMI分为正常体重(18.5-24.9 kg/m2,n=670)、超重(25.0-29.9 kg/m2,n=429)和肥胖(≥30 kg/m2,n=213)。

主要发现

  • BMI每增加5单位,TKV年百分比变化增加1.20%(95%CI 0.85-1.55)。
  • 与正常体重相比,超重者TKV年百分比变化≥7% vs <5%的比值比为2.04(95%CI 1.45-2.87),肥胖者为4.31(95%CI 2.83-6.57)。
  • BMI每增加5单位,eGFR年下降差异为-0.95 ml/min/1.73 m2(95%CI -2.32-0.40),无统计学意义。
  • 治疗×时间×BMI分组三向交互作用对TKV和eGFR均无统计学意义。

关键数值与推荐

  • BMI分类采用正常体重18.5-24.9 kg/m2、超重25.0-29.9 kg/m2、肥胖≥30 kg/m2。
  • TKV年百分比变化≥7% vs <5%的比值比:超重2.04(95%CI 1.45-2.87),肥胖4.31(95%CI 2.83-6.57)。
  • BMI每增加5单位TKV年百分比变化差异1.20%(95%CI 0.85-1.55)。
  • BMI每增加5单位eGFR年下降差异-0.95 ml/min/1.73 m2(95%CI -2.32-0.40)。

临床怎么用

  • 对ADPKD患者应关注超重和肥胖,因其与肾脏体积增长更快相关。
  • 托伐普坦疗效不受BMI分类影响,超重或肥胖患者仍可使用。

局限性

  • 本研究为TEMPO 3:4试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: On the basis of earlier observations, we evaluated the association between overweight and obesity and rapid progression of autosomal dominant polycystic kidney disease in participants in the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 3:4 trial. More importantly, we also determined whether efficacy of tolvaptan was attenuated in individuals with baseline overweight or obesity. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 1312 study participants with relatively early-stage autosomal dominant polycystic kidney disease (mean eGFR 78±22 ml/min per 1.73 m2) who were at high risk of rapid progression were categorized by body mass index (BMI; calculated using nonkidney weight) as normal weight (18.5-24.9 kg/m2; n=670), overweight (25.0-29.9 kg/m2; n=429), or obese (≥30 kg/m2; n=213). Linear and multinomial logistic regression models were used to determine the association of baseline overweight and obesity with change in total kidney volume (TKV) over the 3-year study period. RESULTS: In fully adjusted models, higher BMI was associated with greater annual percent change in TKV (difference of 1.20 [95% confidence interval (95% CI), 0.85 to 1.55] per five-unit higher BMI). Overweight and obesity were associated with higher odds of annual percent change in TKV of ≥7% versus <5% (overweight: odds ratio, 2.04 [95% CI, 1.45 to 2.87]; obese: odds ratio, 4.31 [95% CI, 2.83 to 6.57] versus normal weight). eGFR decline did not differ according to BMI (fully adjusted difference in decline of -0.95 [95% CI, -2.32 to 0.40] ml/min per 1.73 m2 per year per five-unit higher BMI). The three-way interaction (treatment×time×BMI group) was not statistically significant in linear mixed models with an outcome of TKV (log-transformed estimated coefficient comparing the treatment effect for overweight versus normal weight: 0.56% [95% CI, -0.70% to 1.84%] per year; P=0.38; obese versus normal weight: 0.07% [95% CI, -1.47% to 1.63%] per year; P=0.93) or eGFR (estimated coefficient comparing overweight versus normal weight: -0.07 [95% CI, -0.95 to 0.82] ml/min per 1.73 m2 per year; P=0.88; obese versus normal weight: 0.22 [95% CI, -0.93 to 1.36] ml/min per 1.73 m2 per year; P=0.71). CONCLUSIONS: Overweight and particularly obesity are strongly and independently associated with kidney growth, but not eGFR slope, in the TEMPO 3:4 trial, and tolvaptan efficacy is irrespective of BMI categorization. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 3:4, NCT00428948.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Nowak KL, Steele C, Gitomer B, et al. Overweight and Obesity and Progression of ADPKD. Clin J Am Soc Nephrol. 2021. PMID: 34117082. doi:10.2215/CJN.16871020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。